Drug intelligence / Profile preview

Mucosiffa

Development stage: Unknown
Lead developer: Ceva Santé Animale
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Mucosiffa is a swine vaccine that was part of a portfolio of animal health products. This portfolio, originally held by Merial (a Boehringer Ingelheim subsidiary), was divested to Ceva Santé Animale. The divestiture was mandated by the European Commission to address competition concerns arising from a business swap involving Sanofi.

Brand names: Mucosiffa

Targets

BVDV E2 (Bovine viral diarrhea virus glycoprotein E2)

Beyond the preview

Go deeper on Mucosiffa.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mucosiffa.

Explore the full profile